Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Go back to Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

Roche Q3 preview: UBS says 'FX impact turning to a tailwind'

October 21, 2026 6:00 PM EDT

UBS expects limited new strategic news from Roche (OTC: RHHBY) when the Swiss drugmaker reports third-quarter sales on Thursday.

In a preview note, the bank pointed instead to currency effects, key franchises, and competitor readouts as the main focus areas.

Following the recent Pharma Capital Markets Day, we expect limited new news on the strategic positioning of new launches... More